Edition:
United States

Athersys Inc (ATHX.OQ)

ATHX.OQ on NASDAQ Stock Exchange Capital Market

1.94USD
17 Aug 2018
Change (% chg)

$-0.04 (-2.02%)
Prev Close
$1.98
Open
$1.97
Day's High
$1.98
Day's Low
$1.91
Volume
55,620
Avg. Vol
164,986
52-wk High
$3.08
52-wk Low
$1.29

Chart for

About

Athersys, Inc. is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company's MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating... (more)

Overall

Beta: -0.70
Market Cap(Mil.): $268.85
Shares Outstanding(Mil.): 138.58
Dividend: --
Yield (%): --

Financials

  ATHX.OQ Industry Sector
P/E (TTM): -- 99.36 30.45
EPS (TTM): -0.20 -- --
ROI: -55.94 2.89 12.63
ROE: -57.29 1.65 14.82

BRIEF-Athersys Reports Q1 Loss Per Share $0.08

* Q1 REVENUE $1.1 MILLION VERSUS I/B/E/S VIEW $1 MILLION Source text for Eikon: Further company coverage:

May 10 2018

BRIEF-Athersys And Healios Extend By One Month The Period To Complete Collaboration Expansion Agreements

* ATHERSYS AND HEALIOS EXTEND BY ONE MONTH THE PERIOD TO COMPLETE COLLABORATION EXPANSION AGREEMENTS

May 01 2018

BRIEF-Uthealth In Houston And Athersys Announce Funding For Clinical Trial Using Multistem® To Treat Trauma Patients

* UTHEALTH IN HOUSTON AND ATHERSYS ANNOUNCE FUNDING FOR CLINICAL TRIAL USING MULTISTEM® TO TREAT TRAUMA PATIENTS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

Apr 23 2018

BRIEF-Healios K.K. Reports 8.7 Pct Stake In Athersys

* HEALIOS K.K. REPORTS 8.7 PERCENT STAKE IN ATHERSYS INC AS OF MARCH 13, 2018 - SEC FILING‍​ Source text: (https://bit.ly/2G0glmi)

Mar 23 2018

BRIEF-Athersys Reports Q4 Revenue $1.2 Million Versus $1.0 Million

* ATHERSYS REPORTS FINANCIAL RESULTS FOR FOURTH QUARTER, FULL YEAR 2017

Mar 13 2018

Earnings vs. Estimates